CERT Certara

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.

Company management will present at 5:15PM PT on Wednesday, January 15th, 2025.

A live webcast of the event will be available on Certara’s investor relations website at and will be available for replay for at least 30 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
02/01/2025

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara Simcyp® Simulator Becomes First and Only Software Platform to ...

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. Certara is the first company to receive EMA qualification for a PBPK modeling platform, and Simcyp is the only software to hold this designation. The recognition follows a rigorous multi-year, collaborative engagement between ...

12h / 38m 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advan...

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-gene...

July 31, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Report Second Quarter 2025 Financial Results on August 6th,...

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025 RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close on Wednesday, August 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to It is recommended to register at least one day in advance. A live and archived webc...

July 9, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Announces Expansion of Clinical Technology Collaboration with ...

Certara Announces Expansion of Clinical Technology Collaboration with Merck Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement...

July 8, 2025 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports First Quarter 2025 Financial Results

Certara Reports First Quarter 2025 Financial Results Reiterates Full Year 2025 Financial Guidance RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 million, compared to $96.7 million in the first quarter of 2024, representing growth of 10%. Software revenue was $46.4 million, compared to $39.3 million in the first quarter of 2024, representing growth of 18%.Services revenue w...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch